FLT1 and neoplasm: An analysis of tumor growth and weight at endpoint revealed that Flt1 repression in tumor cells re-sensitizes PARPi-resistant tumors to talazoparib (Figs. 3D,E; EV3I), which can be rescued by FLT1 re-expression (EV3K,L).